Symbols / CANF $3.44 +0.29%
CANF Chart
About
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.50M |
| Enterprise Value | -1.82M | Income | -8.80M | Sales | 560.00K |
| Book/sh | 3.16 | Cash/sh | 4.88 | Dividend Yield | — |
| Payout | 0.00% | Employees | 5 | IPO | — |
| P/E | inf | Forward P/E | -4.71 | PEG | — |
| P/S | 8.04 | P/B | 1.09 | P/C | — |
| EV/EBITDA | 0.20 | EV/Sales | -3.24 | Quick Ratio | 3.04 |
| Current Ratio | 3.60 | Debt/Eq | 2.15 | LT Debt/Eq | — |
| EPS (ttm) | 0.00 | EPS next Y | -0.73 | EPS Growth | — |
| Revenue Growth | -36.10% | Earnings | 2025-08-28 08:00 | ROA | -81.86% |
| ROE | -264.12% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -24.25% | Profit Margin | 0.00% | Shs Outstand | 1.31M |
| Shs Float | 1.32M | Short Float | 6.55% | Short Ratio | 1.81 |
| Short Interest | — | 52W High | 36.40 | 52W Low | 3.34 |
| Beta | -0.41 | Avg Volume | 905.61K | Volume | 50.48K |
| Target Price | $50.00 | Recom | Buy | Prev Close | $3.43 |
| Price | $3.44 | Change | 0.29% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$50.00
Mean price target
2. Current target
$3.44
Latest analyst target
3. DCF / Fair value
$-70.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.44
Low
$50.00
High
$50.00
Mean
$50.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-17 | main | D. Boral Capital | Buy → Buy | $4 |
| 2025-11-18 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-09-16 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-09-02 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-07-29 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-15 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-21 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-20 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-03 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-02-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-12-31 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-12-05 | main | D. Boral Capital | Buy → Buy | $10 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-07-17 | init | EF Hutton | — → Buy | $10 |
| 2024-05-09 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2023-10-24 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2023-06-02 | reit | HC Wainwright & Co. | — → Buy | $34 |
| 2023-03-13 | reit | HC Wainwright & Co. | — → Buy | $34 |
- Can-Fite BioPharma (CANF) CEO lists multiple long-dated option grants - Stock Titan Wed, 18 Mar 2026 12
- Why Did CANF Stock Soar 25% Today? - Stocktwits Wed, 04 Mar 2026 08
- CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Yahoo Finance hu, 05 Mar 2026 08
- Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise - The Globe and Mail Wed, 18 Mar 2026 12
- Can-Fite (CANF) director details vested and unvested stock options - Stock Titan Wed, 18 Mar 2026 12
- Can-Fite obesity patent in Israel targets slice of $60.5B market - Stock Titan ue, 17 Mar 2026 11
- [Form 3] Can-Fite BioPharma Ltd. Initial Statement of Beneficial Ownership - Stock Titan Wed, 18 Mar 2026 12
- Early trial finds pancreatic cancer drug from Can-Fite is well tolerated - Stock Titan Wed, 04 Mar 2026 08
- Biotech Can-Fite unlocks $4M to fund drug R&D and clinical trials - Stock Titan Wed, 04 Mar 2026 08
- Can-Fite BioPharma Shareholders Approve All Proposals at March 10 Special Meeting - The Globe and Mail Wed, 11 Mar 2026 22
- Can-Fite BioPharma (NASDAQ: CANF) CSO discloses option and share holdings - Stock Titan Wed, 18 Mar 2026 12
- Can-Fite BioPharma (CANF) VP details option grants in new Form 3 - Stock Titan Wed, 18 Mar 2026 12
- Namodenoson clears Phase 2a safety bar in pancreatic cancer for Can-Fite (CANF) - Stock Titan Wed, 04 Mar 2026 08
- Biotech combines 3,000 shares into 1 in sweeping stock overhaul - Stock Titan ue, 23 Dec 2025 08
- Can-Fite (CANF) shareholders back all three special meeting items - Stock Titan ue, 10 Mar 2026 20
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -8.10M | -8.25M | -9.80M | -13.05M |
| TotalUnusualItems | -27.00K | 69.00K | -283.00K | 221.00K |
| TotalUnusualItemsExcludingGoodwill | -27.00K | 69.00K | -283.00K | 221.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.88M | -7.63M | -10.17M | -12.62M |
| ReconciledDepreciation | 7.00K | 15.00K | 14.00K | 14.00K |
| EBITDA | -8.12M | -8.18M | -10.08M | -12.83M |
| EBIT | -8.13M | -8.20M | -10.10M | -12.84M |
| NetInterestIncome | 277.00K | 492.00K | 206.00K | 6.00K |
| InterestIncome | 291.00K | 506.00K | 222.00K | 24.00K |
| NormalizedIncome | -7.85M | -7.70M | -9.89M | -12.84M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.88M | -7.63M | -10.17M | -12.62M |
| TotalExpenses | 8.80M | 8.94M | 10.91M | 13.70M |
| TotalOperatingIncomeAsReported | -8.13M | -8.20M | -10.10M | -12.84M |
| DilutedAverageShares | 7.25M | 4.26M | 2.72M | 1.84M |
| BasicAverageShares | 7.25M | 4.26M | 2.72M | 1.84M |
| DilutedEPS | 0.00 | -3.00 | -3.00 | -9.00 |
| BasicEPS | 0.00 | -3.00 | -3.00 | -9.00 |
| DilutedNIAvailtoComStockholders | -7.88M | -7.63M | -10.17M | -15.21M |
| NetIncomeCommonStockholders | -7.88M | -7.63M | -10.17M | -15.21M |
| OtherunderPreferredStockDividend | 0.00 | 0.00 | 2.59M | |
| NetIncome | -7.88M | -7.63M | -10.17M | -12.62M |
| NetIncomeIncludingNoncontrollingInterests | -7.88M | -7.63M | -10.17M | -12.62M |
| NetIncomeContinuousOperations | -7.88M | -7.63M | -10.17M | -12.62M |
| TaxProvision | 0.00 | 0.00 | 0.00 | |
| PretaxIncome | -7.88M | -7.63M | -10.17M | -12.62M |
| OtherIncomeExpense | -27.00K | 69.00K | -283.00K | 221.00K |
| GainOnSaleOfSecurity | -27.00K | 69.00K | -283.00K | 221.00K |
| NetNonOperatingInterestIncomeExpense | 277.00K | 492.00K | 206.00K | 6.00K |
| TotalOtherFinanceCost | 14.00K | 14.00K | 16.00K | 18.00K |
| InterestIncomeNonOperating | 291.00K | 506.00K | 222.00K | 24.00K |
| OperatingIncome | -8.13M | -8.20M | -10.10M | -12.84M |
| OperatingExpense | 8.80M | 8.94M | 10.91M | 13.70M |
| ResearchAndDevelopment | 5.76M | 5.98M | 7.76M | 9.85M |
| SellingGeneralAndAdministration | 3.05M | 2.96M | 3.14M | 3.85M |
| GeneralAndAdministrativeExpense | 3.05M | 2.96M | 3.14M | 3.85M |
| OtherGandA | 3.05M | 2.96M | 3.14M | 3.85M |
| TotalRevenue | 674.00K | 743.00K | 810.00K | 853.00K |
| OperatingRevenue | 674.00K | 743.00K | 810.00K | 853.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 2.98B | 1.36B | 815.75M | 815.75M |
| ShareIssued | 2.98B | 1.36B | 815.75M | 815.75M |
| TotalDebt | 104.00K | 40.00K | 62.00K | 124.00K |
| TangibleBookValue | 5.44M | 6.24M | 4.47M | 14.38M |
| InvestedCapital | 5.44M | 6.24M | 4.47M | 14.38M |
| WorkingCapital | 6.93M | 7.89M | 6.66M | 17.34M |
| NetTangibleAssets | 5.44M | 6.24M | 4.47M | 14.38M |
| CapitalLeaseObligations | 104.00K | 40.00K | 62.00K | 124.00K |
| CommonStockEquity | 5.44M | 6.24M | 4.47M | 14.38M |
| TotalCapitalization | 5.44M | 6.24M | 4.47M | 14.38M |
| TotalEquityGrossMinorityInterest | 5.44M | 6.24M | 4.47M | 14.38M |
| StockholdersEquity | 5.44M | 6.24M | 4.47M | 14.38M |
| GainsLossesNotAffectingRetainedEarnings | 1.13M | 1.13M | 1.13M | 1.13M |
| OtherEquityAdjustments | 1.13M | 1.13M | 1.13M | 1.13M |
| RetainedEarnings | -166.36M | -158.48M | -150.85M | -140.67M |
| AdditionalPaidInCapital | 170.67M | 163.60M | 154.19M | 153.93M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 3.68M | 3.75M | 4.81M | 5.87M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.63M | 1.73M | 2.31M | 3.14M |
| NonCurrentDeferredLiabilities | 1.58M | 1.71M | 2.29M | 3.07M |
| NonCurrentDeferredRevenue | 1.58M | 1.71M | 2.29M | 3.07M |
| LongTermDebtAndCapitalLeaseObligation | 51.00K | 13.00K | 14.00K | 71.00K |
| LongTermCapitalLeaseObligation | 51.00K | 13.00K | 14.00K | 71.00K |
| CurrentLiabilities | 2.05M | 2.02M | 2.50M | 2.73M |
| CurrentDeferredLiabilities | 405.00K | 622.00K | 783.00K | 818.00K |
| CurrentDeferredRevenue | 405.00K | 622.00K | 783.00K | 818.00K |
| CurrentDebtAndCapitalLeaseObligation | 53.00K | 27.00K | 48.00K | 53.00K |
| CurrentCapitalLeaseObligation | 53.00K | 27.00K | 48.00K | 53.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 675.00K | 694.00K | 492.00K | 603.00K |
| PayablesAndAccruedExpenses | 919.00K | 677.00K | 1.18M | 1.26M |
| CurrentAccruedExpenses | 301.00K | 250.00K | 283.00K | 302.00K |
| Payables | 618.00K | 427.00K | 896.00K | 954.00K |
| AccountsPayable | 618.00K | 427.00K | 896.00K | 954.00K |
| TotalAssets | 9.12M | 9.99M | 9.28M | 20.25M |
| TotalNonCurrentAssets | 138.00K | 81.00K | 126.00K | 185.00K |
| NetPPE | 138.00K | 81.00K | 126.00K | 185.00K |
| AccumulatedDepreciation | -52.00K | -263.00K | -248.00K | -234.00K |
| GrossPPE | 190.00K | 344.00K | 374.00K | 419.00K |
| Leases | 0.00 | 13.00K | 13.00K | 13.00K |
| OtherProperties | 64.00K | 62.00K | 62.00K | 62.00K |
| MachineryFurnitureEquipment | 126.00K | 269.00K | 299.00K | 344.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 8.98M | 9.91M | 9.16M | 20.07M |
| OtherCurrentAssets | 1.09M | 986.00K | 1.17M | 929.00K |
| PrepaidAssets | 908.00K | 1.12M | 881.00K | |
| Receivables | 47.00K | 48.00K | ||
| OtherReceivables | 47.00K | 48.00K | ||
| CashCashEquivalentsAndShortTermInvestments | 7.89M | 8.92M | 7.99M | 19.14M |
| OtherShortTermInvestments | 3.06M | 4.64M | 5.01M | 14.75M |
| CashAndCashEquivalents | 4.83M | 4.28M | 2.98M | 4.39M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -7.64M | -8.44M | -10.81M | -9.87M |
| IssuanceOfCapitalStock | 6.71M | 9.14M | 0.00 | 20.46M |
| CapitalExpenditure | -5.00K | -2.00K | -9.00K | -11.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 18.00K | |
| EndCashPosition | 4.83M | 4.28M | 2.98M | 4.39M |
| BeginningCashPosition | 4.28M | 2.98M | 4.39M | 8.27M |
| EffectOfExchangeRateChanges | -22.00K | 98.00K | -113.00K | 34.00K |
| ChangesInCash | 569.00K | 1.20M | -1.30M | -3.91M |
| FinancingCashFlow | 6.71M | 9.14M | 0.00 | 20.46M |
| CashFlowFromContinuingFinancingActivities | 6.71M | 9.14M | 0.00 | 20.46M |
| NetCommonStockIssuance | 6.71M | 9.14M | 0.00 | 20.46M |
| CommonStockIssuance | 6.71M | 9.14M | 0.00 | 20.46M |
| InvestingCashFlow | 1.50M | 498.00K | 9.50M | -14.51M |
| CashFlowFromContinuingInvestingActivities | 1.50M | 498.00K | 9.50M | -14.51M |
| NetInvestmentPurchaseAndSale | 1.50M | 500.00K | 9.51M | -14.50M |
| PurchaseOfInvestment | -14.50M | |||
| NetPPEPurchaseAndSale | -5.00K | -2.00K | -9.00K | -11.00K |
| PurchaseOfPPE | -5.00K | -2.00K | -9.00K | -11.00K |
| OperatingCashFlow | -7.64M | -8.44M | -10.80M | -9.86M |
| CashFlowFromContinuingOperatingActivities | -7.64M | -8.44M | -10.80M | -9.86M |
| ChangeInWorkingCapital | -267.00K | -943.00K | -1.30M | 2.43M |
| ChangeInOtherWorkingCapital | -349.00K | -743.00K | -810.00K | 1.40M |
| ChangeInOtherCurrentLiabilities | -32.00K | -84.00K | -62.00K | -63.00K |
| ChangeInOtherCurrentAssets | 55.00K | |||
| ChangeInPayablesAndAccruedExpense | 223.00K | -300.00K | -188.00K | 967.00K |
| ChangeInPayable | 223.00K | -300.00K | -188.00K | 967.00K |
| ChangeInAccountPayable | 191.00K | -469.00K | -58.00K | 393.00K |
| ChangeInPrepaidAssets | -109.00K | 184.00K | -241.00K | 128.00K |
| OtherNonCashItems | 90.00K | -222.00K | 113.00K | -46.00K |
| StockBasedCompensation | 362.00K | 261.00K | 263.00K | 466.00K |
| UnrealizedGainLossOnInvestmentSecurities | 14.00K | -11.00K | 229.00K | -162.00K |
| AssetImpairmentCharge | 37.00K | 94.00K | 54.00K | 55.00K |
| DepreciationAmortizationDepletion | 7.00K | 15.00K | 14.00K | 14.00K |
| DepreciationAndAmortization | 7.00K | 15.00K | 14.00K | 14.00K |
| Depreciation | 7.00K | 15.00K | 14.00K | 14.00K |
| OperatingGainsLosses | 68.00K | |||
| NetForeignCurrencyExchangeGainLoss | 68.00K | |||
| NetIncomeFromContinuingOperations | -7.88M | -7.63M | -10.17M | -12.62M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for CANF
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|